FY2025 EPS Estimates for Septerna Lowered by HC Wainwright

Septerna, Inc. (NASDAQ:SEPN) – Equities research analysts at HC Wainwright lowered their FY2025 EPS estimates for Septerna in a report released on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.53) per share for the year, down from their prior forecast of ($1.45). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Septerna’s current full-year earnings is ($7.11) per share. HC Wainwright also issued estimates for Septerna’s Q4 2025 earnings at ($0.16) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.61) EPS and FY2026 earnings at ($1.67) EPS.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The firm had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million.

A number of other research analysts have also recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. Raymond James Financial assumed coverage on Septerna in a report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price objective for the company. Wall Street Zen downgraded Septerna from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 10th. Truist Financial initiated coverage on Septerna in a research report on Monday, December 15th. They set a “buy” rating and a $34.00 target price for the company. Finally, Wells Fargo & Company upgraded shares of Septerna from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $18.00 to $28.00 in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $33.83.

Septerna Price Performance

Septerna stock opened at $25.76 on Thursday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -17.06 and a beta of 3.85. Septerna has a 1-year low of $4.17 and a 1-year high of $30.50. The company’s 50-day moving average is $26.76 and its 200 day moving average is $19.75.

Hedge Funds Weigh In On Septerna

Institutional investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. bought a new stake in shares of Septerna in the third quarter valued at about $673,000. PharVision Advisers LLC raised its holdings in shares of Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after purchasing an additional 1,780 shares in the last quarter. VR Adviser LLC raised its holdings in shares of Septerna by 13.0% in the 3rd quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock valued at $11,489,000 after purchasing an additional 70,355 shares in the last quarter. Verition Fund Management LLC purchased a new stake in shares of Septerna in the 3rd quarter worth approximately $379,000. Finally, Millennium Management LLC boosted its stake in shares of Septerna by 639.6% during the third quarter. Millennium Management LLC now owns 384,200 shares of the company’s stock valued at $7,227,000 after purchasing an additional 332,256 shares in the last quarter.

Insiders Place Their Bets

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the sale, the senior vice president directly owned 92,911 shares in the company, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by company insiders.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.